The prevention of pneumococcal disease by vaccines: Promises and challenges

Infectious Disease Clinics of North America

Volumn 15, Issue 1, 2001, Pages 97-122

  Poland, Gregory A ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PNEUMOCOCCUS VACCINE; PNU IMMUNE 23;

ADOLESCENT; ADULT; AGED; CHILD; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG SAFETY; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; REVIEW; STREPTOCOCCUS INFECTION; VACCINATION;

EID: 0035062690     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70270-1     Document Type: Article

References (143)

1. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era
2. Responses to influenza vaccine in HIV infected children and influence on viral replication
3. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants
4. Human adult immunogenicity of protein-coupled pneumococcal capsular antigens of serotypes prevalent in otitis media
5. Prevention of pneumococcal pneumonia by vaccination
6. Chemo-immunological studies on conjugated carbohydrate-proteins. II. Immunological specificity of synthetic sugar-protein antigens
7. Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy
8. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine
9. Colonization by Streptococcus pneumoniae among human immunodeficiency virus-infected adults: Prevalence of antibiotic resistance, impact of immunization, and characterization by polymerase chain reaction with BOX primers of isolates from persistent S. pneumoniae carriers
10. Community-acquired pneumonia
11. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
12. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants
13. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants
14. Emergence of drug-resistant pneumococcal infections in the United States
15. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine
16. Efficacy of pneumococcal polysaccharide vaccines
17. Epidemiology of pneumococcal serotypes and conjugate vaccine formulations
18. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations
19. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: Implications for development of a conjugate vaccine
20. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: An update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System
21. The Hawaii pneumoccocal disease initiative
22. Pneumococcal vaccine
23. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients
24. Reasons reported by medicare beneficiaries for not receiving influenza and pneumococcal vaccinations - United States, 1996
25. Vaccine-preventable diseases: Improving vaccination coverage in children, adolescents, and adults
26. Pneumococcal and influenza vaccination levels among adults aged ≥ 65 years - United States, 1995
27. Influenza and pneumococcal vaccination levels among adults aged >65 years - United States, 1997
28. Prevention and control of influenza. Recommendations of the Advisory Committee on Imunization Practices
29. Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
30. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease
31. A strategy to improve the utilization of pneumococcal vaccine
32. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine
33. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B,14,19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens
34. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid
35. Immunogenicity of pneumococcal revaccination in patients with chronic disease
36. Effect of Haemophilus influenzae type b immunization on HIV viremia in HIV-seropositive adults
37. Immunogenicity of pneumococcal conjugate vaccines
38. FinOM efficacy trial of 7-valent pneumococcal conjugate vaccine
39. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study
40. Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid
41. Improving the use of pneumoccocal vaccine through a strategy of hospital-based immunization: A review of its rationale and implications
42. Influenza and pneumococcal immunization strategies for physicians
43. Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996
44. Pneumococcal vaccination for older adults. The first 20 years
45. Pneumococcal conjugate vaccination for adults: Why it's important for children
46. Hospital-based pneumococcal immunization. Epidemiologic rationale from the Shenandoah Study
47. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials
48. Inefficacy of pneumococcal vaccine in a high-risk population
49. Immunization of adults
50. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients
51. Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex
52. The effect of influenza vaccination on human immunodeficiency virus type 1 load: A randomized, double-blind, placebo-controlled study
53. Polysaccharide conjugate vaccine responses in bone marrow transplant patients
54. The contribution of specific pneumococcal serogroups to different disease manifestations: Implications for conjugate vaccine formulation and use, part III
55. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I
56. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly
57. The impact of vaccination strategy and methods of information on influenza and pneumococcal vaccination coverage in the elderly population
58. Antibody responses after influenza and pneumococcal immunization in HIV infected homosexual men
59. Safety of revaccination with pneumococcal polysaccharide vaccine
60. Should patients positive for HIV infection receive pneumococcal vaccine?
61. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus Type 1
62. Revaccination with polyvalent pneumococcal vaccine in children with sickle cell anemia
63. Assessments of plasma HIV RNA and CD4 cell counts after combined Pneumovax and tetanus toxoid vaccination: No detectable disease in HIV replication 6 weeks after immunization
64. Pneumonia in old age: Active immunization against pneumonia with pneumococcus polysaccharide - Results of a six year study
65. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children
66. New vaccines for the prevention of pneumococcal infections
67. Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus
68. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children
69. Pneumococcal conjugate vaccines: Review and update
70. An effective hospital-based pneumococcal immunization program
71. Clinical efficacy of pneumococcal vaccine in the elderly: A randomized, single-blind population-based trial
72. The importance of G1m and 2 allotypes for the IgG2 antibody levels and avidity against pneumococcal polysaccharide type 1 within mono- and dizygotic twin-pairs
73. Influenza and pneumococcal immunizations. How to deliver the goods
74. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy
75. + lymphocytes
76. Pneumococcal vaccine in normal children
77. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants
78. Effect of pneumococcal vaccine on morbidity from acute lower respiratory tract infections in Papua New Guinean children
79. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children
80. Pneumococcal vaccination in patients with HIV infection
81. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides
82. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination
83. Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine
84. Pneumococcal antibody levels one decade after immunization of healthy adults
85. Antimicrobial resistance in Streptococcus pneumoniae: Can immunization prevent its spread?
86. Antibody to capsular polysaccharides of Streptococcus pneumoniae: Prevalence, persistence, and response to revaccination
87. Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides
88. IgG responses to protein-conjugated pneumococcal capsular polysaccharides in persons who are genetically incapable of responding to unconjugated polysaccharides
89. Temporal evaluation of specific antibody response to vaccination with Pneumovax™ in HIV infected patients
90. A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae
91. Side effects associated with pneumococcal vaccination
92. Cigarette smoking and invasive pneumococcal disease
93. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California
94. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines
95. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination
96. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in the prevention of pneumonia in middle-aged and elderly people
97. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps
98. Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers
99. Franklin County Pneumonia Study Group: Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention
100. The burden of pneumococcal disease: The role of conjugate vaccines
101. Call to action: Improving influenza and pneumococcal immunization rates among high-risk adults
102. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults
103. Underutilization of pneumococcal vaccine in nursing homes in Washington state: Report of a serotype-specific outbreak and a survey
104. Pneumococcal vaccine trials in Papua New Guinea: Relationships between epidemiology of pneumococcal infection and efficacy of vaccine
105. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children
106. Immunisation with a polyvalent pneumococcal vaccine
107. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine
108. Colonization by Streptococcus pneumoniae among human immunodeficiency virus-infected adults: Prevalence of antibiotic resistance, impact of immunization, and characterization by polymerase chain reaction with BOX primers of isolates from persistent S. pneumoniae carriers
109. Safety of pneumococcal revaccination
110. Influenza and pneumococcal vaccination of HIV-infected patients: A policy analysis
111. Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered simultaneously in the elderly
112. IgG subclasses of pneumococcal antibodies - Effect of allotype G2m(n)
113. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide - Tetanus toxoid conjugates
114. Serogroup-specific epidemiology of Streptococcus pneumoniae: Associations with age, sex, and geography in 7,000 episodes of invasive disease
115. Pneumococcal vaccine failure
116. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
117. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections
118. 197 conjugated pneumococcal oligosaccharide vaccines in young and elderly adults
119. Efficacy of pneumococcal conjugate vaccines in large scale trials
120. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
121. 197 conjugate vaccine in infants and toddlers
122. Pneumococcal disease: Prospects for a new generation of vaccines
123. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration cooperative study
124. The clinical effectiveness of pneumococcal vaccine in the elderly
125. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people
126. Protective efficacy of pneumococcal polysaccharide vaccines
127. The American Diabetes Association position statement on immunization and the prevention of influenza and pneumococcal disease in people with diabetes
128. Use of influenza, and pneumococcal vaccines in people with diabetes
129. Is there any connection between a second pneumonia shot and hospitalization among Medicare beneficiaries?
130. Thymus-independent and thymus-dependent responses to polysaccharide antigens
131. Glycoconjugate vaccines: What next?
132. A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: Effect of polysaccharide size and linkage characteristics
133. Equal IgG antibody response to pneumococcal vaccination in all stages of human immunodeficiency virus disease
134. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine
135. Influenza immunization of HW-1-infected patients does not increase HIV-1 viral load
136. Antigenic stimulation by immunization does not increase HIV viral load
137. Epidemiology of invasive pneumococcal disease in Southern California: Implications for the design and conduct of a pneumoccal conjugate vaccine efficacy trial